bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
Read More
Cancer diagnostics
To detect cancer at its earliest and more treatable stage, different types of diagnostic tests are used to:
- Screen an asymptomatic population for the early detection of cancer
- Screen at-risk individuals
- Diagnose a primary cancer and identify the cancer subtype
- Predict prognosis and direct treatment
- Monitor treatment efficacy and disease progression or recurrence
Earlier detection and treatment subsequently decreases cancer mortality.
bioMérieux contributes to the management of cancer by providing a wide range of high-value tools for screening, diagnosis and monitoring of different cancer types:
bioMerieux offer for diagnosing cancer
|
Cancer
|
Available Tumor Markers
|
| Breast Cancer |
CA 15-3, CEA |
| Cervical Cancer |
Detection of active HPV oncogenes (E6 / E7 mRNA) |
| Colorectal Cancer |
CEA |
| Prostate Cancer |
Total PSA, free PSA |
| Other Cancers: Liver, Ovary and Pancreatic Cancers, Germ cell cancers (Choriocarcinoma, testicular cancer), white blood cells-related cancers |
AFP, CA 19-9, CA 125, hCG, beta2 –Microglobulin |
bioMérieux Research and Development in the field of Cancer
bioMérieux is committed to developing new tools that improve early detection of cancer and help clinicans make relevant clinical decisions in their daily pratice.
Over the past years, R&D programs have been implemented in collaboration with high level biotechnology companies (Affymetrix®, NorChip®, ExonHit® …) and leading academic groups to identify clinically relevant biomarkers and profiling signatures.
|